Skip to main content

PD-L1, IHC (Nivolumab)

Test Number 480588
Test number copied
CPT 88360
Synonyms
  • Opdivo®
  • Programmed Death Ligand 1

Test Details

Methodology

Immunohistochemistry (IHC)

Result Turnaround Time

5 - 9 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Special Instructions

Note: This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete, based on the processes performed in the laboratory.

Specimen Requirements

Specimen

Tissue

Volume

One formalin-fixed paraffin-embedded (FFPE) tissue block or five unstained positively charged slides sectioned from FFPE tissue block at 4 to 5 microns.

Minimum Volume

Three unstained tissue slides

Collection Instructions

Tissue should be fixed in 10% neutral buffered formalin for no more than 72 hours. Embed in paraffin.

Storage Instructions

Room temperature

Causes for Rejection

Insufficient tissue; tumor other than non-small-cell lung cancer

References

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407
Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796
Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109.
Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
480588 PD-L1 IHC, OPDIVO(R) 85148-5 480578 Result 83055-4
480588 PD-L1 IHC, OPDIVO(R) 85148-5 480579 % Tumor Cells Staining: % 83053-9
480588 PD-L1 IHC, OPDIVO(R) 85148-5 480584 Comments: 77202-0
480588 PD-L1 IHC, OPDIVO(R) 85148-5 480586 Interpretation: 77202-0
480588 PD-L1 IHC, OPDIVO(R) 85148-5 480587 Director Review 72486-4
Order Code480588
Order Code NamePD-L1 IHC, OPDIVO(R)
Order Loinc85148-5
Result Code480578
Result Code NameResult
UofM
Result LOINC83055-4
Order Code480588
Order Code NamePD-L1 IHC, OPDIVO(R)
Order Loinc85148-5
Result Code480579
Result Code Name% Tumor Cells Staining:
UofM%
Result LOINC83053-9
Order Code480588
Order Code NamePD-L1 IHC, OPDIVO(R)
Order Loinc85148-5
Result Code480584
Result Code NameComments:
UofM
Result LOINC77202-0
Order Code480588
Order Code NamePD-L1 IHC, OPDIVO(R)
Order Loinc85148-5
Result Code480586
Result Code NameInterpretation:
UofM
Result LOINC77202-0
Order Code480588
Order Code NamePD-L1 IHC, OPDIVO(R)
Order Loinc85148-5
Result Code480587
Result Code NameDirector Review
UofM
Result LOINC72486-4